Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.

Guardado en:
Detalles Bibliográficos
Autores principales: Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares